US 11,969,485 B2
Controlled release of radionuclides
Itzhak Kelson, Tel Aviv (IL); Yona Keisari, Ramat Gan (IL); Michael Schmidt, Kfar Saba (IL); Amnon Gat, Matan (IL); Ofer Magen, Hod Hasharon (IL); Guy Keret, Beit Yehoshua (IL); Amitai Sosnovitch, Nokdim (IL); and Avia Berkowitz, Modiin (IL)
Assigned to ALPHA TAU MEDICAL LTD., Jerusalem (IL)
Appl. No. 16/979,543
Filed by ALPHA TAU MEDICAL LTD., Tel Aviv (IL)
PCT Filed Mar. 28, 2019, PCT No. PCT/IB2019/052524
§ 371(c)(1), (2) Date Sep. 10, 2020,
PCT Pub. No. WO2019/193464, PCT Pub. Date Oct. 10, 2019.
Claims priority of provisional application 62/651,274, filed on Apr. 2, 2018.
Prior Publication US 2021/0008233 A1, Jan. 14, 2021
Int. Cl. A61K 51/12 (2006.01); A61K 9/00 (2006.01); A61N 5/10 (2006.01)
CPC A61K 51/1282 (2013.01) [A61N 5/1001 (2013.01); A61K 9/0004 (2013.01); A61K 9/0009 (2013.01); A61K 9/0024 (2013.01)] 49 Claims
OG exemplary drawing
 
1. A brachytherapy device, comprising:
a seed base adapted for being at least partially introduced into a body of a subject; and
a plurality of radionuclide atoms of a first alpha-emitting isotope, coupled to the seed base, such that at least 0.1%, but not more than 25% of the plurality of radionuclide atoms coupled to the seed base leave the seed base in 24 hours, without radioactive decay,
wherein daughter nuclei of the plurality of radionuclide atoms are released from the seed base upon radioactive decay.